COREY MALMGREN
COREY MALMGREN is named as a lobbyist in 34 lobbying reports we hold, filed by 1 registrant for 34 clients.
Earlier government jobs, as reported
A lobbying report lists each lobbyist's covered positions: jobs in Congress or the executive branch that the law asks a lobbyist to disclose. Each line is copied as a report states it.
No report we hold lists a covered position for COREY MALMGREN.
Registrants and clients
- TIBER CREEK GROUP · 34 reports
Clients: ACADEMY OF MANAGED CARE PHARMACY; ACADIA PHARMACEUTICALS, INC.; ACCOUNTABLE FOR HEALTH; AGILON HEALTH, INC.; ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS; ALNYLAM PHARMACEUTICALS, INC.; AMGEN INC; ASSOCIATION FOR CLINICAL ONCOLOGY; ASTELLAS PHARMA US, INC.; ASTRAZENECA; BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.); CORROHEALTH, INC.; DAIICHI SANKYO, INC.; DH DIAGNOSTICS LLC; ELEVANCE HEALTH, INC.; EMD SERONO, INC.; GILEAD SCIENCES, INC.; HUMANA, INC.; INCYTE CORPORATION; MERCK & CO., INC; MYRIAD GENETICS, INC.; NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS (FKA NAHU); ORGANON, LLC; PATIENT SQUARE CAPITAL; PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION; PHLOW CORPORATION; PHRMA; SIEMENS HEALTHINEERS; SOLVENTUM CORPORATION; TAKEDA PHARMACEUTICALS AMERICA, INC.; THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION); TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY); TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS); UNITED THERAPEUTICS CORPORATION.
Bills named where this lobbyist is listed, and how the House and the Senate voted
39 bills named in these reports. None of them became law in our record, so no recorded vote is shown. A lobbying report names the houses of Congress and the agencies the lobbyists contacted. It does not say which members or staff they met.
| Bill | Status | How the House and the Senate voted |
|---|---|---|
| H.R. 946ORPHAN Cures Act | Introduced | No recorded vote in our record |
| H.R. 1492To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. | Introduced | No recorded vote in our record |
| H.R. 1672Maintaining Investments in New Innovation Act | Introduced | No recorded vote in our record |
| H.R. 3164Ensuring Community Access to Pharmacist Services Act | Introduced | No recorded vote in our record |
| H.R. 3288Access to Prescription Digital Therapeutics Act of 2025 | Introduced | No recorded vote in our record |
| H.R. 3514Improving Seniors’ Timely Access to Care Act of 2025 | Introduced | No recorded vote in our record |
| H.R. 3890Resident Physician Shortage Reduction Act of 2025 | Introduced | No recorded vote in our record |
| H.R. 3955RAPID Reserve Act | Introduced | No recorded vote in our record |
| H.R. 4191MAPS Act | Introduced | No recorded vote in our record |
| H.R. 4299Protecting Patient Access to Cancer and Complex Therapies Act | Introduced | No recorded vote in our record |
| H.R. 5269RESULTS Act | Introduced | No recorded vote in our record |
| H.R. 5526Biosimilar Red Tape Elimination Act | Introduced | No recorded vote in our record |
| H.R. 6130ASAP Act | Introduced | No recorded vote in our record |
| H.R. 6197Health Tech Investment Act | Introduced | No recorded vote in our record |
| H.R. 6509SAFE Drugs Act of 2025 | Introduced | No recorded vote in our record |
| H.R. 7352PASTEUR Act of 2026 | Introduced | No recorded vote in our record |
| H.R. 7871MVP Act | Introduced | No recorded vote in our record |
| H.R. 8129To amend title XVIII of the Social Security Act to establish a full risk ACO program. | Introduced | No recorded vote in our record |
| H.R. 8800National Defense Authorization Act for Fiscal Year 2027 | Passed the House | No recorded vote in our record |
| H.R. 8857Next GEN Act of 2026 | Introduced | No recorded vote in our record |
| H.Res. 1331Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week". | Introduced | No recorded vote in our record |
| S. 1041Affordable Prescriptions for Patients Act | Passed the Senate | No recorded vote in our record |
| S. 1096Preserve Access to Affordable Generics and Biosimilars Act | Reported by committee | No recorded vote in our record |
| S. 1399Health Tech Investment Act | Introduced | No recorded vote in our record |
| S. 1637MVP Act | Introduced | No recorded vote in our record |
| S. 1702Access to Prescription Digital Therapeutics Act of 2025 | Introduced | No recorded vote in our record |
| S. 1784MAPS Act | Introduced | No recorded vote in our record |
| S. 1816Improving Seniors’ Timely Access to Care Act of 2025 | Introduced | No recorded vote in our record |
| S. 1862ORPHAN Cures Act | Introduced | No recorded vote in our record |
| S. 1954Biosimilar Red Tape Elimination Act | Reported by committee | No recorded vote in our record |
| S. 2062RAPID Reserve Act | Introduced | No recorded vote in our record |
| S. 2426Equitable Community Access to Pharmacist Services Act | Introduced | No recorded vote in our record |
| S. 2439Resident Physician Shortage Reduction Act of 2025 | Introduced | No recorded vote in our record |
| S. 2658Medication Affordability and Patent Integrity Act | Reported by committee | No recorded vote in our record |
| S. 2761RESULTS Act | Introduced | No recorded vote in our record |
| S. 3097Health Information Privacy Reform Act | Reported by committee | No recorded vote in our record |
| S. 3267ASAP Act | Introduced | No recorded vote in our record |
| S. 4784National Defense Authorization Act for Fiscal Year 2027 | Reported by committee | No recorded vote in our record |
| S. 4875PASTEUR Act of 2026 | Introduced | No recorded vote in our record |
Issues named: Health Issues (26), Medicare/Medicaid (26), Budget/Appropriations (4), Trade (domestic/foreign) (3), Copyright/Patent/Trademark (1), Taxation/Internal Revenue Code (1).
Every report
| Client | Registrant | Kind, as filed | Posted | Report |
|---|---|---|---|---|
| ACADIA PHARMACEUTICALS, INC.Health Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| SIEMENS HEALTHINEERSHealth Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| DH DIAGNOSTICS LLCMedicare/Medicaid, Budget/Appropriations, Health Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| UNITED THERAPEUTICS CORPORATIONHealth Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| ACADEMY OF MANAGED CARE PHARMACYHealth Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| PATIENT SQUARE CAPITALHealth Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY)Medicare/Medicaid, Health Issues, Copyright/Patent/Trademark | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS (FKA NAHU)Health Issues, Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION)Medicare/Medicaid, Health Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| ELEVANCE HEALTH, INC.Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| ASSOCIATION FOR CLINICAL ONCOLOGYHealth Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| CORROHEALTH, INC.Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| AGILON HEALTH, INC.Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| ACCOUNTABLE FOR HEALTHMedicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| TAKEDA PHARMACEUTICALS AMERICA, INC.Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| PHRMAMedicare/Medicaid, Trade (domestic/foreign), Health Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| MERCK & CO., INCMedicare/Medicaid, Trade (domestic/foreign), Health Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDSHealth Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| INCYTE CORPORATIONMedicare/Medicaid, Health Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| EMD SERONO, INC.Health Issues, Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| ASTRAZENECAHealth Issues, Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| AMGEN INCMedicare/Medicaid, Health Issues | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| ALNYLAM PHARMACEUTICALS, INC.Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| SOLVENTUM CORPORATIONHealth Issues, Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| PHLOW CORPORATIONHealth Issues, Budget/Appropriations | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATIONHealth Issues, Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| ORGANON, LLCHealth Issues, Medicare/Medicaid, Budget/Appropriations | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| MYRIAD GENETICS, INC.Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| HUMANA, INC.Medicare/Medicaid, Taxation/Internal Revenue Code | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| GILEAD SCIENCES, INC.Health Issues, Medicare/Medicaid, Budget/Appropriations | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| DAIICHI SANKYO, INC.Health Issues, Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.)Health Issues, Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| ASTELLAS PHARMA US, INC.Health Issues, Medicare/Medicaid | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov | |
| TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)Medicare/Medicaid, Health Issues, Trade (domestic/foreign) | TIBER CREEK GROUP | 2nd Quarter - Report | The report on LDA.gov |
Campaign gifts this lobbyist reported
Lobbyists and registrants report their political contributions twice a year (form LD-203). We hold these reports only for contributions to the campaign committees of members who sponsored or cosponsored a bill named in a lobbying report. Any other contribution: Not checked yet.
| Member | Paid to, as reported | Amount | Date | Report |
|---|---|---|---|---|
| Sarah McBride DDemocrat | MCBRIDE FOR DELAWARE, INCFrom SELF | $1,000 | The report on LDA.gov |
Where this comes from
Lobbying Disclosure Act reports (LD-2), LDA.gov. We save our own copy of each page of LDA.gov's list of reports before we read it. These pages were built from our copies on .
2026-Q2: every page of LDA.gov's list saved and read.
A lobbying report states the registrant's income from the client (a lobbying firm) or its own lobbying expenses (an organization lobbying for itself), for the whole quarter and every issue together. A report of less than $5,000, or of no lobbying activity, states no figure. It is not the amount spent on one bill.
Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.